A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Latest Information Update: 31 Jan 2025
At a glance
- Drugs Darolutamide (Primary) ; Goserelin; Leuprorelin; Triptorelin
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ERADICATE
Most Recent Events
- 28 Jan 2025 Planned primary completion date changed from 30 Jun 2025 to 31 Dec 2025.
- 10 Dec 2024 Planned primary completion date changed from 31 May 2028 to 30 Jun 2025.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.